Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials
Lay Summary Crohn’s disease is a chronic, lifelong condition, but there has been a notable absence of long-term data from clinical trials, with outcomes typically focused on shorter-term outcomes at 6 months, at 1 year, or at most 2 years. The growing amount of longer-term data from clinical trial programs is therefore welcome and valuable for patients to help guide on selection of appropriate therapies and treatment strategies.
Authors
- Sara El Ouali (ORCID: https://orcid.org/0000-0001-6153-1081)
- Joseph Sleiman (ORCID: https://orcid.org/0000-0002-7390-5949)
- Nurulamin M Noor (ORCID: https://orcid.org/0000-0003-3426-6408)
Institutions
- Cleveland Clinic (US)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Cambridge School (PT)
- MRC Clinical Trials Unit at UCL (GB)
- Abu Dhabi Health Services (AE)
- University College London (GB)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1093/ibd/izag073
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer